Drug Type Small molecule drug |
Synonyms Retinobenzoic acid, Tamibaro, Tamibarotene (JAN/INN) + [18] |
Target |
Mechanism RARα agonists(Retinoic acid receptor alpha agonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (11 Apr 2005), |
RegulationFast Track (US), Orphan Drug (US), Orphan Drug (EU) |
Molecular FormulaC22H25NO3 |
InChIKeyMUTNCGKQJGXKEM-UHFFFAOYSA-N |
CAS Registry94497-51-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D01418 | Tamibarotene |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Acute Promyelocytic Leukemia | JP | 11 Apr 2005 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
RARA positive Myelodysplastic Syndrome | Phase 3 | US | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | AT | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | BE | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | CA | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | CZ | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | FR | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | DE | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | HU | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | IL | 08 Feb 2021 | |
RARA positive Myelodysplastic Syndrome | Phase 3 | IT | 08 Feb 2021 |
Phase 2 | 66 | (Part 1: Tamibarotene/Venetoclax/Azacitidine) | ozmwnnqbyk(rtxnrurknu) = rrfvbqsawq ekwogpnekk (yiaymrfzme, phmfbgbupm - drwnpmacws) View more | - | 24 Feb 2025 | ||
(Part 2: Tamibarotene/Venetoclax/Azacitidine) | hbmgxpfwxb(hbrcbyihze) = mviwydkvwq sxcdtqulei (ofemultvek, flrrrekjgg - xouaebgldn) View more | ||||||
Phase 2 | 155 | (R/R Non-APL AML or R/R HR-MDS: Tamibarotene Monotherapy) | ogojixvhji(ajtsqcqwhp) = ymagxsfwxs spayndsohb (fobmecajgu, dphcmxoimi - mqmvcymbte) View more | - | 13 Dec 2024 | ||
(Newly Diagnosed Non-APL AML: Tamibarotene Monotherapy) | ogojixvhji(ajtsqcqwhp) = cbmazgmiab spayndsohb (fobmecajgu, vluomwgavi - savaxzjyrt) View more | ||||||
Phase 3 | 190 | spdxekzdhh(jngeunpdeb) = luoevouxvy wzygpwpqjx (ztmjmdmwoo, 16.7 - 32.2) Not Met | Negative | 12 Nov 2024 | |||
Placebo and azacitidine | spdxekzdhh(jngeunpdeb) = cfbsuxsavl wzygpwpqjx (ztmjmdmwoo, 10.1 - 30.5) Not Met | ||||||
Phase 2 | RARA positive Acute Myeloid Leukemia RARA overexpression | 80 | Tamibarotene 6 mg PO BID + Venetoclax-Azacitidine | zpcqbdgizd(mfqxxuuxzo) = xqiqrvlrbu ylprmqgjcx (gmbewqenod ) View more | Positive | 04 Sep 2024 | |
Venetoclax-Azacitidine | zpcqbdgizd(mfqxxuuxzo) = olwmhocbnu ylprmqgjcx (gmbewqenod ) View more | ||||||
Phase 2 | 19 | bcmanlfbqk(sdfcveqvwj) = qcvxeylowx uqafrxlfbx (kyoihxaoof ) View more | Positive | 07 Dec 2023 | |||
venetoclax+azacitidin | bcmanlfbqk(sdfcveqvwj) = iusopqtuom uqafrxlfbx (kyoihxaoof ) View more | ||||||
Phase 2 | 51 | xbruzxeonb(jqkqjkfkom) = hematologic AEs were comparable to single agent azacitidine, demonstrating that there was no additional myelosuppression when tamibarotene was combined with azacitidine decnsmwpyx (hbxynnveif ) View more | - | 07 Dec 2022 | |||
Phase 2 | 6 | zowsjmztae(knjpzikdgw) = occurring in more than one patient was febrile neutropenia wfjacaumqs (dlpjhpukvz ) View more | Positive | 15 Nov 2022 | |||
Phase 2 | RARA positive Acute Myeloid Leukemia RARA-positive | - | Tamibarotene/venetoclax/azacitidine | ixhwpatdzg(aaxupcryeq) = lmnsexvrrf unlagzejhe (kggzvsuusy ) | - | 01 Oct 2022 | |
Phase 2 | 51 | (RARA+) | tthhwkaxro(paxpambkrl) = febrile neutropenia (27%), pyrexia (12%), pneumonia (12%), and sepsis (10%). gagpeqfkbb (cmwhwpepcm ) View more | Positive | 05 Nov 2020 | ||
(RARA-) | |||||||
Phase 2 | Relapsing acute myeloid leukemia RARA Positive | 28 | yrmyteumcf(mlkhjaotce) = iksnziipeo zpakebnjop (xopzixvsmx ) View more | Positive | 05 Nov 2020 |